A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults.
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Escherichia coli vaccine (Primary)
- Indications Enterotoxigenic Escherichia coli infections; Traveller's diarrhoea
- Focus Pharmacodynamics
- Sponsors Intercell USA; Valneva USA
- 11 Dec 2017 According to a Valneva media release, Intercell USA changed its name to Valneva USA.
- 18 Apr 2014 Primary endpoints and drug dosage have been added as reported by ClinicalTrials.gov record.
- 12 Aug 2010 Actual end date (November 2009) added as reported by ClinicalTrials.gov.